Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.60 |
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.55 |
| ▸ | FNTB | P49356 | 1/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15458722 | 0.88 | HIF1A (0.67) | HIF1AFFAR1KMT2AHDAC8HDAC6 | |
| SCHEMBL17158376 | 0.86 | HIF1A (0.64) | HIF1AFFAR1HDAC1FFAR4FNTA | |
| SCHEMBL20183490 | 0.86 | PPARA (0.66) | HIF1AFFAR1MEN1KMT2APPARA | |
| SCHEMBL20183707 | 0.85 | PPARA (0.65) | FFAR1MEN1KMT2APPARA | |
| SCHEMBL11257944 | 0.84 | FFAR1 (0.71) | EPHX2NR1H4FFAR1HDAC1FFAR4 | |
| SCHEMBL10055040 | 0.84 | FFAR1 (0.68) | HIF1AFFAR1PPARAMRGPRX4 | |
| SCHEMBL31227759 | 0.83 | PPARA (0.73) | FFAR1PPARA | |
| SCHEMBL2185809 | 0.83 | FFAR1 (0.70) | HIF1AFFAR1KMT2AHDAC8HDAC6 | |
| SCHEMBL1287947 | 0.83 | HIF1A (0.83) | HIF1AFFAR1KMT2AHDAC8HDAC6 | |
| SCHEMBL17158378 | 0.81 | FFAR1 (0.57) | NR1H4HIF1AFFAR1FFAR4FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| CN-108349875-B | Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient | 东国大学校产学协力团 | 2021-08-27 | — | — | CN | disclosed |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-08-02 | — | — | US | disclosed |
| EP-3327001-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | EPHX2 1068/4885NR1H4 851/4885HIF1A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.